Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.35
QGEN's Cash to Debt is ranked lower than
78% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. QGEN: 0.35 )
Ranked among companies with meaningful Cash to Debt only.
QGEN' s 10-Year Cash to Debt Range
Min: 0.31  Med: 0.95 Max: N/A
Current: 0.35
Equity to Asset 0.61
QGEN's Equity to Asset is ranked higher than
53% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. QGEN: 0.61 )
Ranked among companies with meaningful Equity to Asset only.
QGEN' s 10-Year Equity to Asset Range
Min: 0.44  Med: 0.61 Max: 0.72
Current: 0.61
0.44
0.72
Interest Coverage 4.09
QGEN's Interest Coverage is ranked lower than
88% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1009.34 vs. QGEN: 4.09 )
Ranked among companies with meaningful Interest Coverage only.
QGEN' s 10-Year Interest Coverage Range
Min: 2.05  Med: 9.22 Max: 53.96
Current: 4.09
2.05
53.96
F-Score: 6
Z-Score: 3.31
M-Score: -2.61
WACC vs ROIC
6.57%
4.93%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 11.11
QGEN's Operating margin (%) is ranked higher than
78% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. QGEN: 11.11 )
Ranked among companies with meaningful Operating margin (%) only.
QGEN' s 10-Year Operating margin (%) Range
Min: 4.86  Med: 14.61 Max: 23.8
Current: 11.11
4.86
23.8
Net-margin (%) 7.92
QGEN's Net-margin (%) is ranked higher than
78% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.06 vs. QGEN: 7.92 )
Ranked among companies with meaningful Net-margin (%) only.
QGEN' s 10-Year Net-margin (%) Range
Min: 5.31  Med: 10.15 Max: 15.62
Current: 7.92
5.31
15.62
ROE (%) 4.08
QGEN's ROE (%) is ranked higher than
59% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.27 vs. QGEN: 4.08 )
Ranked among companies with meaningful ROE (%) only.
QGEN' s 10-Year ROE (%) Range
Min: 2.49  Med: 12.73 Max: 20.73
Current: 4.08
2.49
20.73
ROA (%) 2.46
QGEN's ROA (%) is ranked higher than
61% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.44 vs. QGEN: 2.46 )
Ranked among companies with meaningful ROA (%) only.
QGEN' s 10-Year ROA (%) Range
Min: 1.65  Med: 6.83 Max: 14.11
Current: 2.46
1.65
14.11
ROC (Joel Greenblatt) (%) 20.27
QGEN's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. QGEN: 20.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
QGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 10.11  Med: 38.22 Max: 73.31
Current: 20.27
10.11
73.31
Revenue Growth (3Y)(%) 6.70
QGEN's Revenue Growth (3Y)(%) is ranked higher than
54% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. QGEN: 6.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
QGEN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -2.2  Med: 10.00 Max: 44.5
Current: 6.7
-2.2
44.5
EBITDA Growth (3Y)(%) 9.30
QGEN's EBITDA Growth (3Y)(%) is ranked higher than
66% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. QGEN: 9.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
QGEN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -9.1  Med: 11.50 Max: 48.8
Current: 9.3
-9.1
48.8
EPS Growth (3Y)(%) 8.60
QGEN's EPS Growth (3Y)(%) is ranked higher than
60% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. QGEN: 8.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
QGEN' s 10-Year EPS Growth (3Y)(%) Range
Min: -22.5  Med: 13.90 Max: 47.4
Current: 8.6
-22.5
47.4
» QGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

QGEN Guru Trades in Q3 2014

PRIMECAP Management 22,080,114 sh (-0.03%)
Manning & Napier Advisors, Inc 2,226,305 sh (-1.13%)
Jim Simons 217,000 sh (-41.67%)
» More
Q4 2014

QGEN Guru Trades in Q4 2014

PRIMECAP Management 22,284,066 sh (+0.92%)
Jim Simons Sold Out
Manning & Napier Advisors, Inc 2,224,435 sh (-0.08%)
» More
Q1 2015

QGEN Guru Trades in Q1 2015

Paul Tudor Jones 9,500 sh (New)
Jim Simons 33,656 sh (New)
PRIMECAP Management 22,731,216 sh (+2.01%)
Manning & Napier Advisors, Inc 2,162,732 sh (-2.77%)
» More
Q2 2015

QGEN Guru Trades in Q2 2015

Manning & Napier Advisors, Inc 2,471,378 sh (+14.27%)
Paul Tudor Jones 9,500 sh (unchged)
Jim Simons Sold Out
PRIMECAP Management 22,703,966 sh (-0.12%)
» More
» Details

Insider Trades

Latest Guru Trades with QGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 63.51
QGEN's P/E(ttm) is ranked lower than
89% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.70 vs. QGEN: 63.51 )
Ranked among companies with meaningful P/E(ttm) only.
QGEN' s 10-Year P/E(ttm) Range
Min: 23.17  Med: 39.96 Max: 149.96
Current: 63.51
23.17
149.96
Forward P/E 21.93
QGEN's Forward P/E is ranked lower than
58% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.33 vs. QGEN: 21.93 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 62.20
QGEN's PE(NRI) is ranked lower than
89% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.80 vs. QGEN: 62.20 )
Ranked among companies with meaningful PE(NRI) only.
QGEN' s 10-Year PE(NRI) Range
Min: 23.26  Med: 39.57 Max: 147.89
Current: 62.2
23.26
147.89
P/B 2.35
QGEN's P/B is ranked higher than
64% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. QGEN: 2.35 )
Ranked among companies with meaningful P/B only.
QGEN' s 10-Year P/B Range
Min: 1.19  Med: 1.84 Max: 2.63
Current: 2.35
1.19
2.63
P/S 4.69
QGEN's P/S is ranked lower than
68% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. QGEN: 4.69 )
Ranked among companies with meaningful P/S only.
QGEN' s 10-Year P/S Range
Min: 2.8  Med: 4.01 Max: 5.49
Current: 4.69
2.8
5.49
PFCF 24.72
QGEN's PFCF is ranked lower than
52% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.00 vs. QGEN: 24.72 )
Ranked among companies with meaningful PFCF only.
QGEN' s 10-Year PFCF Range
Min: 19.02  Med: 34.75 Max: 56.51
Current: 24.72
19.02
56.51
POCF 15.69
QGEN's POCF is ranked higher than
73% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.49 vs. QGEN: 15.69 )
Ranked among companies with meaningful POCF only.
QGEN' s 10-Year POCF Range
Min: 11.72  Med: 18.35 Max: 30.99
Current: 15.69
11.72
30.99
EV-to-EBIT 52.48
QGEN's EV-to-EBIT is ranked lower than
89% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.91 vs. QGEN: 52.48 )
Ranked among companies with meaningful EV-to-EBIT only.
QGEN' s 10-Year EV-to-EBIT Range
Min: 17.4  Med: 40.20 Max: 100.8
Current: 52.48
17.4
100.8
PEG 311.00
QGEN's PEG is ranked lower than
100% of the 41 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. QGEN: 311.00 )
Ranked among companies with meaningful PEG only.
QGEN' s 10-Year PEG Range
Min: 2.08  Med: 3.65 Max: 91.29
Current: 311
2.08
91.29
Shiller P/E 61.34
QGEN's Shiller P/E is ranked lower than
80% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.93 vs. QGEN: 61.34 )
Ranked among companies with meaningful Shiller P/E only.
QGEN' s 10-Year Shiller P/E Range
Min: 24.16  Med: 43.22 Max: 67.17
Current: 61.34
24.16
67.17
Current Ratio 3.51
QGEN's Current Ratio is ranked higher than
60% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. QGEN: 3.51 )
Ranked among companies with meaningful Current Ratio only.
QGEN' s 10-Year Current Ratio Range
Min: 1.45  Med: 3.08 Max: 6.29
Current: 3.51
1.45
6.29
Quick Ratio 2.98
QGEN's Quick Ratio is ranked higher than
63% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. QGEN: 2.98 )
Ranked among companies with meaningful Quick Ratio only.
QGEN' s 10-Year Quick Ratio Range
Min: 1.18  Med: 2.54 Max: 5.75
Current: 2.98
1.18
5.75
Days Inventory 100.87
QGEN's Days Inventory is ranked lower than
62% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.06 vs. QGEN: 100.87 )
Ranked among companies with meaningful Days Inventory only.
QGEN' s 10-Year Days Inventory Range
Min: 94.1  Med: 139.51 Max: 296.11
Current: 100.87
94.1
296.11
Days Sales Outstanding 71.76
QGEN's Days Sales Outstanding is ranked lower than
60% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. QGEN: 71.76 )
Ranked among companies with meaningful Days Sales Outstanding only.
QGEN' s 10-Year Days Sales Outstanding Range
Min: 46.36  Med: 63.18 Max: 76.79
Current: 71.76
46.36
76.79

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.97
QGEN's Price/Projected FCF is ranked higher than
52% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.94 vs. QGEN: 1.97 )
Ranked among companies with meaningful Price/Projected FCF only.
QGEN' s 10-Year Price/Projected FCF Range
Min: 1.03  Med: 1.50 Max: 1.89
Current: 1.97
1.03
1.89
Price/Median PS Value 1.08
QGEN's Price/Median PS Value is ranked lower than
73% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. QGEN: 1.08 )
Ranked among companies with meaningful Price/Median PS Value only.
QGEN' s 10-Year Price/Median PS Value Range
Min: 0.74  Med: 1.00 Max: 1.31
Current: 1.08
0.74
1.31
Earnings Yield (Greenblatt) (%) 1.90
QGEN's Earnings Yield (Greenblatt) (%) is ranked higher than
55% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. QGEN: 1.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
QGEN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1  Med: 2.50 Max: 5.7
Current: 1.9
1
5.7
Forward Rate of Return (Yacktman) (%) -2.35
QGEN's Forward Rate of Return (Yacktman) (%) is ranked lower than
82% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.53 vs. QGEN: -2.35 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
QGEN' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -2.5  Med: 7.90 Max: 13.9
Current: -2.35
-2.5
13.9

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 1,313 1,392 1,455
EPS($) 1.08 1.20 1.30
EPS without NRI($) 1.08 1.20 1.30

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:0H1Z.UK, QIA.Germany,
Qiagen NV provides Sample & Assay Technologies, based on market studies of United States and European market shares for its products and technologies. It also offers kits, assays, related automated systems and bioinformatics solutions, that cover the entire continuum from basic life sciences research to clinical diagnostics. The Company markets more than 500 core products that are distributed in thousands of variations and combinations. In October 2012, the company announced a collaboration with Bayer HealthCare for development and commercialization of companion diagnostics paired with novel Bayer drugs, initially to enhance the treatment of various solid tumors. The Company has developed and advanced a broad range of technologies to extract and purify molecules of interest from biological samples such as blood, bone, tissue. It has also developed assays that enable the analysis of various kinds of molecules from virtually any biological sample. Assay technologies make information contained in isolated molecules visible and available for interpretation. The Company sells varied and flexible workflows for molecular testing, including sample and assay kits known as consumables and automated instrumentation platforms using those technologies, to four major customer classes: Molecular Diagnostics - healthcare providers supporting many aspects of patient care including prevention, profiling of diseases, personalized healthcare and point of need testing; Applied Testing - government or industry customers using molecular technologies in fields such as forensics, veterinary diagnostics and food safety testing; Pharma - drug discovery, translational medicine and clinical development efforts of pharmaceutical and biotechnology companies; Academia - researchers exploring the secrets of life such as the mechanisms and pathways of diseases. The Company markets its products in more than 100 countries throughout the world. The Company's competitors includes Promega Corp., EMD Millipore or Merck Millipore, and Macherey-Nagel GmbH for nucleic acid separation and purification; Thermo Fisher and Promega Corp. for assay solutions and for transfection reagents; and Sigma-Aldrich Corp. and Thermo Fisher for protein fractionation products. The Company is subject to a variety of laws and regulations in the European Union, the United States and other countries.
» More Articles for QGEN

Headlines

Articles On GuruFocus.com
Seegene and QIAGEN Enter Into a Collaboration to Develop Multiplex Molecular Diagnostic Assays Jul 08 2015 
comment on QGEN May 14 2013 
comment on QGEN May 10 2013 
Biotech Gets Personal: Long on Qiagen (QGEN) & SPDR S&P Biotech (XBI) Feb 29 2012 
Guru Stocks at 52-Week Lows: LMT, VIP, VMC, IRM, QGEN Oct 10 2010 
Weekly Guru Bargains Highlights: QGEN, BXS, ATHR, LYV, TFSL Oct 09 2010 

More From Other Websites
Edited Transcript of QGEN earnings conference call or presentation 30-Oct-13 1:30pm GMT Sep 04 2015
QIAGEN kit isolates high-quality RNA from exosomes in liquid biopsies Sep 03 2015
RainDance pulls IPO citing market conditions Aug 24 2015
Healthcare and Pharmaceuticals Prevail in Stable Market Conditions Aug 12 2015
Qiagen (QGEN) Beats Q2 Earnings, Revenues; Keeps '15 View - Analyst Blog Jul 31 2015
Edited Transcript of QGEN earnings conference call or presentation 30-Jul-15 1:30pm GMT Jul 30 2015
QIAGEN reports results for second quarter and first half of 2015 Jul 29 2015
QIAGEN Reports Results for Second Quarter and First Half of 2015 Jul 29 2015
QIAGEN N.V. to Report Second Quarter 2015 Results Jul 16 2015
Qiagen's EGFR Test Gets PMA Nod to Treat Lung Cancer - Analyst Blog Jul 14 2015
QIAGEN companion diagnostic wins FDA approval for use with IRESSA Jul 13 2015
QIAGEN Companion Diagnostic Wins FDA Approval for use With IRESSA Jul 13 2015
Qiagen Rides High on Collaborations, Test Menu Expansion - Analyst Blog Jul 13 2015
Qiagen Inks Molecular Diagnostics Partnership with Seegene - Analyst Blog Jul 09 2015
Seegene and QIAGEN Enter Into a Collaboration to Develop Multiplex Molecular Diagnostic Assays Jul 08 2015
QIAGEN Expands QIAsymphony Test Menu in Partnership with Seegene Jul 08 2015
QIAGEN and Biotype Diagnostics form partnership Jun 26 2015
Implementation of the Mandatory Squeeze-out for the Shares of QIAGEN Marseille Jun 25 2015
Qiagen, Hitachi High-Technologies Ink Molecular Testing Deal - Analyst Blog Jun 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK